Pharmacotherapy of neuropathic pain: Which drugs, which treatment algorithms?

Pain

Volumn 156, Issue 4, 2015, Pages S104-S114

  Attal, Nadine ^a,b   Bouhassira, Didier ^a,b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

Clinical trials; Neuropathic pain; Pharmacotherapy; Phenotypic subgrouping; Therapeutic algorithms

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BOTULINUM TOXIN A; CANNABINOID; CAPSAICIN; GABAPENTIN; LIDOCAINE; OPIATE; PREGABALIN; TAPENTADOL; TRAMADOL; ANALGESIC AGENT;

ALGORITHM; COMPARATIVE STUDY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; NEUROPATHIC PAIN; PATIENT CODING; PLACEBO EFFECT; PREDICTION; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ANALGESIA; ANIMAL; DRUG COMBINATION; META ANALYSIS (TOPIC); NEURALGIA; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALGORITHMS; ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; META-ANALYSIS AS TOPIC; NEURALGIA; PAIN MANAGEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84939807695     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/01.j.pain.0000460358.01998.15     Document Type: Review

References (97)

1. Attal N, Bouhassira D, Baron R, Dostrovsky J, Dworkin RH, Finnerup N, Gourlay G, Haanpaa M, Raja S, Rice AS, Simpson D, Treede RD. Assessing symptom profiles in neuropathic pain clinical trials: Can it improve outcome? Eur J Pain 2011;15:441-3.
2. Attal N, Cruccu G, Baron R, HaanpääM, Hansson P, Jensen TS, Nurmikko T; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain. 2010 revision. Eur J Neurol 2010;17:1113-e88.
3. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P; EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13: 1153-69.
4. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? PAIN 2008;138:343-53.
5. Attal N, Gaudé V, Brasseur L, Dupuy M, Guirimand F, Parker F, Bouhassira D. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology 2000;54:564-74.
6. Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: Results of a French nationwide survey. PAIN 2011;152:2836-43.
7. Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 2004;62:218-25.
8. Backonja MM, Attal N, Baron R, Bouhassira D, Drangholt M, Dyck PJ, EdwardsRR, Freeman R, Gracely R, HaanpaaMH, Hansson P, HatemSM, Krumova EK, Jensen TS, Maier C, Mick G, Rice AS, Rolke R, Treede RD, Serra J, Toelle T, Tugnoli V, Walk D, Walalce MS, Ware M, Yarnitsky D, Ziegler D. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. PAIN 2013;154:1807-19.
9. Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009;26:1019-26.
10. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9: 807-19.
11. Baron R, Forster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol 2012;11:999-1005.
12. Baron R, Tölle TR, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. PAIN 2009;146:34-40.
13. Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393-408.
14. Bohnert AS, Ilgen MA, Trafton JA, Kerns RD, Eisenberg A, Ganoczy D, Blow FC. Trends and regional variation in opioid overdose mortality among veterans health administration patients, fiscal year 2001 to 2009. Clin J Pain 2013;30:605-12.
15. Bouhassira D. Neuropathic pain: the clinical syndrome revisited. Acta Neurol Belg 2001;101:47-52.
16. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lanteri-Minet M, Collin E, Grisart J, Boureau F. Development and validation of the Neuropathic Pain Symptom Inventory. PAIN 2004; 108:248-57.
17. Bouhassira D, Attal N. Novel strategies for neuropathic pain. In: Villanueva L, Dickenson A, Ollat H, editors. The pain system in normal and pathological states: a primer for clinicians. Progress in Pain Research and Management, Volume 31, Seattle: IASP Press, 2004.
18. Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: the saga of clinical tools. PAIN 2011;152:S74-83.
19. Bouhassira D, Lanté ri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. PAIN 2008;136:380-7.
20. Bouhassira D, Wilhelm S, Schacht A, Perrot S, Kosek E, Cruccu G, Freynhagen R, Tesfaye S, Lledó A, Choy E, Marchettini P, Micó JA, Spaeth M, Skljarevski V, Tölle T. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. PAIN 2014;155: 2171-9.
21. Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, Feldman E, Iverson DJ, Perkins B, Russell JW, Zochodne D; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758-65.
22. Buchmuller A, Navez M, Milletre-Bernardin M, Pouplin S, Presles E, Lanté ri-Minet M, Tardy B, Laurent B, Camdessanché JP; Lombotens Trial Group. Value of TENS for relief of chronic low back pain with or without radicular pain. Eur J Pain 2012;16:656-65.
23. Buss T, Leppert W. Opioid-induced endocrinopathy in cancer patients: an underestimated clinical problem. Adv Ther 2014;31:153-67.
24. Campbell CM, Kipnes MD, Stouch BC, Brady KL, Kelly M, Schmidt WK, Petersen KL, Rowbotham MC, Campbell JN. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. PAIN 2012; 153:1815-23.
25. Cardenas DD, Nieshoff EC, Suda K, Goto S, Sanin L, Kaneko T, Sporn J, Parsons B, Soulsby M, Yang R, Whalen E, Scavone JM, Suzuki MM, Knapp LE. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology 2013;5:533-9.
26. Cepeda MS, Berlin JA, Gao CY, Wiegand F, Wada DR. Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-Analysis. Pain Med 2012;13:575-95.
27. Davis GP, Compton MT, Wang S, Levin FR, Blanco C. Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Schizophr Res 2013;151:197-202.
28. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, Jensen TS, Sindrup SH. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebocontrolled phenotype-stratified study. PAIN 2014;155:2263-73.
29. Derry S, Sven-Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2013;2:CD007393.
30. Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review andmeta-Analysis of health utilities. PAIN 2010; 149:338-44.
31. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004;63:959-65.
32. Dworkin RH,O'Connor AB, BackonjaM, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC,Wallace MS. Pharmacologic management of neuropathic pain: evidence evidence-based recommendations. PAIN 2007;132:237-51.
33. Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations? PAIN 2012;153:869-75.
34. Dworkin RH, Turk DC, Peirce-Sandner S, He H,McDermott MP, Farrar JT, Katz NP, Lin AH, Rappaport BA, Rowbotham MC. Assay sensitivity and study features in neuropathic pain trials: an ACTTION meta-Analysis. Neurology 2013;81:67-75.
35. Edlund MJ,Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain 2014;30:557-64.
36. Edwards RR, Haythornthwaite JA, Tella P, Max MB, Raja S. Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology 2006;104:1243-8.
37. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-Analysis of randomized controlled trials. JAMA 2005; 293:3043-52.
38. Etropolski M, Kuperwasser B, Flügel M, Häufel T, Lange B, Rauschkolb C, Laschewski F. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. Adv Ther 2014;31:604-20.
39. Farrar JT, Troxel AB, Haynes K,Gilron I, Kerns RD, KatzNP,Rappaport BA, Rowbotham MC, Tierney AM, Turk DC, Dworkin RH. Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study. PAIN 2014;155: 1622-31.
40. Farrar JT, Young JP Jr., LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. PAIN 2001;94:149-58.
41. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SR, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith B, Wallace M. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-Analysis and NeuPSIG recommendations. Lancet Neurol 2015. Jan 6. [epub ahead of print].
42. Finnerup NB, Biering-Sorensen F, Johannesen IL, Terkelsen AJ, Juhl GI, Kristensen AD, Sindrup SH, Bach FW, Jensen TS. Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. Anesthesiology 2005;102:1023-30.
43. Finnerup NB, Jensen TS. Mechanisms of disease: mechanism-based classification of neuropathic pain-A critical analysis. Nat Clin Pract Neurol 2006;2:107-15.
44. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. PAIN 2002;96:375-83.
45. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. PAIN 2010;150:573-81.
46. Fischer B, Jones W, Urbanoski K, Skinner R, Rehm J. Correlations between prescription opioid analgesic dispensing levels and related mortality and morbidity in Ontario, Canada, 2005-2011. Drug Alcohol Rev 2014;33:19-26.
47. Freeman R, Baron R, Bouhassira D, Cabrera J, Emir B. Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. PAIN 2014;155:367-76.
48. Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374:1252-61.
49. Gilron I, Jensen TS, Dickenson AH. Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurol 2013;12:1084.
50. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
51. Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, Cruccu G, Hansson P, Haythornthwaite JA, Iannetti GD, Jensen TS, Kauppila T, Nurmikko TJ, Rice AS, Rowbotham M, Serra J, Sommer C, Smith BH, Treede RD. NeuPSIG guidelines on neuropathic pain assessment. PAIN 2011;152:14-27.
52. Hall W, Degenhardt L. Cannabis and the increased incidence and persistence of psychosis. BMJ 2011;342:d719.
53. Hansson P. Difficulties in stratifying neuropathic pain by mechanisms. Eur J Pain 2003;7:353-7.
54. Hatem SM, Attal N, Ducreux D, Gautron M, Parker F, Plaghki L, Bouhassira D. Clinical, functional and structural determinants of central pain in syringomyelia. Brain 2010;133:3409-22.
55. Herrmann DN, Pannoni V, Barbano RL, Pennella-Vaughan J, Dworkin RH. Skin biopsy and quantitative sensory testing do not predict response to lidocaine patch in painful neuropathies. Muscle Nerve 2006;33: 42-8.
56. Kalliomäki J, Attal N, Jonzon B, Bach FW, Huizar K, Ratcliffe S, Eriksson B, Janecki M, Danilov A, Bouhassira D; AZD2423 PTN Study Group. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. PAIN 2013;154: 761-7.
57. Katz J, Finnerup NB, Dworkin RH. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology 2008;70:263-72.
58. Kim JS, Bashford G, Murphy TK, Martin A, Dror V, Cheung R. Safety and efficacy of pregabalin in patients with central post-stroke pain. PAIN 2011;152:1018-23.
59. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S. A double-blind, randomized, placebo-controlled, parallelgroup study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013;260:984-97.
60. Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, Gross J, Gold MS, Dickenson AH, Feng G, Luo ZD. Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. PAIN 2006; 125:20-34.
61. Liang J, Liu X, Zheng J, Yu S. Effect of amitriptyline on tetrodotoxinresistant Nav1.9 currents in nociceptive trigeminal neurons. Mol Pain 2013;9:31.
62. Lund K, Vase L, Petersen GL, Jensen TS, Finnerup NB. Randomised controlled trials may underestimate drug effects: balanced placebo trial design. PLoS ONE 2014;9:e84104.
63. Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, WilliamsME, Yaksh TL. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlationwith allodynia in spinal nerve-injured rats. J Neurosci 2001;21:1868-75.
64. MaierC,Baron R, Tölle TR,Binder A,Birbaumer N,Birklein F, Gierthmühlen J, Flor H, Geber C, Huge V, Krumova EK, Landwehrmeyer GB, Magerl W, Maihöfner C, Richter H, Rolke R, Scherens A, Schwarz A, Sommer C, Tronnier V, Uçeyler N, Valet M, Wasner G, Treede RD. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. PAIN 2010;150:439-50.
65. Martinez V, Attal N, Vanzo B, Vicaut E, Gautier JM, Bouhassira D, Lanté ri-Minet M. Adherence of French GPs to Chronic Neuropathic Pain Clinical Guidelines: results of a cross-sectional, randomized, "e" case-vignette survey. PLoS ONE 2014;9:e93855.
66. Max MB. Is mechanism-based pain treatment attainable? Clinical trial issues. J Pain 2000;1(3 suppl):2-9.
67. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;4:CD007938.
68. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014;19:328-35.
69. NICE. clinical guideline: Neuropathic pain-pharmacological management. 2013. Available at: http:/guidance nice org uk/CG173. Accessed June 24, 2014.
70. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. PAIN 1999;81:135-45.
71. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. PAIN 2007; 133:210-20.
72. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain: a double blind placebo controlled study. Ann Neurol 2008;64:274-83.
73. Rauck R, Makumi CW, Schwartz S, Graff O, Meno-Tetang G, Bell CF, Kavanagh ST, McClung CL. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract 2013;13:485-96.
74. Rice AS, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G, Desem N, Raff M; EMA401-003 study group. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 2014;383:1637-47.
75. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-9.
76. RomanóCL, RomanóD, Bonora C, Mineo G. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol 2009;10:185-91.
77. Rowbotham MC. Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology 2005;65(12 suppl 4):S66-73.
78. Schiltenwolf M, Akbar M, Hug A, Pfüller U, Gantz S, Neubauer E, Flor H, Wang H. Evidence of specific cognitive deficits in patients with chronic low back pain under long-term substitution treatment of opioids. Pain Physician 2014;17:9-20.
79. Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomizedwithdrawal, placebo-controlled trial. Curr Med Res Opin 2011;27: 151-62.
80. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005;19:187-94.
81. SimpsonDM, Schifitto G,CliffordDB,MurphyTK, Durso-DeCruz E, Glue P, Whalen E, Emir B, Scott GN, Freeman R; 1066 HIV Neuropathy Study Group. 1066 HIV Neuropathy Study Group. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 2010;74:413-20.
82. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL; Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309: 1359-67.
83. Smith BH, Torrance N. Epidemiology of neuropathic pain and its impact on quality of life. Curr Pain Headache Rep 2012;16:191-8.
84. Tan T, Barry P, Reken S, Reken S, Baker M; Guideline Development Group. Pharmacological management of neuropathic pain in nonspecialist settings: summary of NICE guidance. Br Med J 2010;340: c1079.
85. Tesfaye S, WilhelmS, Lledo A, Schacht A, Tölle T, Bouhassira D, Cruccu G, Skljarevski V, Freynhagen R. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"-A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. PAIN 2013;154: 2616-25.
86. Torrance N, Ferguson JA, Afolabi E, Bennett MI, Serpell MG, Dunn KM, Smith BH. Neuropathic pain in the community: more under-treated than refractory? PAIN 2013;154:690-9.
87. TreedeRD, Jensen TS,Campbell JN, Cruccu G, Dostrovsky JO,GriffinJW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70:1630-5.
88. Truini A, Biasiotta A, La Cesa S, Di Stefano G, Galeotti F, Petrucci MT, Inghilleri M, Cartoni C, Pergolini M, Cruccu G. Mechanisms of pain in distal symmetric polyneuropathy: a combined clinical and neurophysiological study. PAIN 2010;150:516-21.
89. Truini A, Garcia-Larrea L, Cruccu G. Reappraising neuropathic pain in humans-how symptoms help disclose mechanisms. Nat Rev Neurol 2013;9:572-82.
90. Vinik AI, Shapiro DY, Rauschkolb C, Lange B, Karcher K, Pennett D, Etropolski MS. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care 2014;37:2302-9.
91. Vollmer TL, Robinson MJ, Risser RC, Malcolm SK. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. Pain Pract 2014;14: 732-44.
92. von Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73:638-52.
93. Vranken J, Hollmann MW, van der Vegt MH, et al. Duloxetine in patients with central neuropathic pain: a randomized, double-blind, placebocontrolled trial of a flexible-dose regimen. PAIN 2010;152:267-73.
94. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev 2009;60:267-77.
95. Woolf CJ. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci 2004; 74:2605-10.
96. Woolf CJ, Bennett GJ, Doherty M, Dubner R, Kidd B, Koltzenburg M, Lipton R, Loeser JD, Payne R, Torebjork E. Towards a mechanism-based classification of pain? PAIN 1998;77:227-9.
97. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M. Beta(2)-Adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol 2009;65: 218-25.